Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

103.84 +0.75 (+0.73%)
Streaming Delayed Price Updated: 3:49 PM EST, Dec 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,278,876
Open 102.86
Bid (Size) 103.84 (1)
Ask (Size) 103.85 (4)
Prev. Close 103.09
Today's Range 102.33 - 105.07
52wk Range 94.48 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.97%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer
Merck's ovarian cancer trial met its primary endpoint, while lymphoma trial data set the Phase 3 dose for zilovertamab vedotin at 1.75 mg/kg. 
Via Benzinga
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire

Performance

YTD
-8.30%
-8.30%
1 Month
+0.90%
+0.90%
3 Month
-10.02%
-10.02%
6 Month
-21.02%
-21.02%
1 Year
-0.50%
-0.50%

More News

Read More
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
From Merck & Co., Inc.
Via Business Wire
Merck & Co Unusual Options Activity For December 02
Via Benzinga
Why NYSE:MRK provides a good dividend, while having solid fundamentals.
Via Chartmill
2 Healthcare Dividend Stocks to Hold for the Long Haul
Via The Motley Fool
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday
Via The Motley Fool
Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults
From Merck & Co., Inc.
Via Business Wire
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Via The Motley Fool
3 Ultra-Cheap Dividend Stocks to Buy in December
Via The Motley Fool
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Via Benzinga
FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations
From Merck & Co., Inc.
Via Business Wire
The Smartest Dividend Stocks to Buy With $3,000 Right Now
Via The Motley Fool
The Data Shows Three Market-Jolting Forces On The Move
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Interest Rates
Merck to Participate in the Citi 2024 Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Why Is Merck Stock Trading Higher On Monday?
Via Benzinga
Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis
From Merck & Co., Inc.
Via Business Wire
Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer
From Merck & Co., Inc.
Via Business Wire
Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference
From Merck & Co., Inc.
Via Business Wire
Merck’s WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
From Merck & Co., Inc.
Via Business Wire
Surendralal Karsanbhai Elected to Merck Board of Directors
From Merck & Co., Inc.
Via Business Wire
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
Via Benzinga
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
Via The Motley Fool
Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities
From Merck & Co., Inc.
Via Business Wire
NYSE:MRK appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.